How to Test <i>HER2</i> for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405-Reference-Cited by-同舟云学术

How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405

Published:2024-07-30 Issue: Volume: Page:
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sartore-Bianchi Andrea¹^ORCID,Marsoni Silvia¹^ORCID,Amatu Alessio¹^ORCID,Torri Valter¹^ORCID,Bonoldi Emanuela¹,Bardelli Alberto¹^ORCID,Trusolino Livio¹^ORCID,Siena Salvatore¹^ORCID

Affiliation:

1. Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS—The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, “Mario...

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.24.00805

Reference7 articles.

1. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405

2. The genomic landscape of response to EGFR blockade in colorectal cancer

3. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

4. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas